Floatz logo

Cyclophosphamide

Bone Marrow Failure Syndrome

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2/3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Bone Marrow Failure Syndrome cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2/3BBB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2BB
Busulfanum
Memorial Sloan Kettering Cancer Center
Phase 2/3BB
Alemtuzumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3BB
Methotrexate
Fred Hutchinson Cancer Center
Phase 2BB

View all 30 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
mycosis fungoidesActive
BBB
Indicative · Phase 4
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →